Last updated: October 5, 2023.
We can't believe you want to read this.
Solt DB Invest provides information compiled by amateur investors. That means we don't have any fancy financial qualifications. We aren't professional financial advisors, portfolio managers, or stock brokers.
Although our intention is for all analysts to earn a Chartered Financial Analyst (CFA) charter, none of our analysts currently have a charter. There can be no guarantee they'll be smart or disciplined enough to earn one. I mean, look at us.
Solt DB Invest doesn't make stock recommendations. We don't introduce new companies with "Buy" recommendations, issue "triple-down buy alerts," promise "up to 8x returns by 2028," or advertise "rare all-in buy alerts." Those are the other guys.
We compile information to help make sense of the complex intersection of finance and biotech. If you buy or sell a stock, then that is your decision to make.
Stocks go up. Stocks go down. Stocks go sideways. Many individual stocks don't outperform popular benchmarks, such as the S&P 500. That includes many stocks in the Solt DB Invest coverage ecosystem.
Biotech stocks are inherently volatile, especially prior to generating meaningful revenue or achieving profitable operations. Solt DB Invest has historically covered small-cap stocks, which are among the riskiest and most volatile investments on the stock market.
Financial information, including stock price data, is provided by Twelve Data. You can read Twelve Data's terms on their website. You really like reading, huh?
-cropped.svg)
.svg){kind=small}
.svg){kind=small}
.svg)